What one share of Trevi Therapeutics holds
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC.
Trevi Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.34 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.36 |
| Cash and investments | $2.24 |
| Book value | $2.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$58.45 | $0.36 | −$42.15 | — | −$249.64 |
| 2019 | — | −$2.28 | $0.00 | −$1.97 | — | $3.06 |
| 2020 | — | −$1.81 | $0.00 | −$1.61 | — | $1.47 |
| 2021 | — | −$1.49 | — | — | — | $0.60 |
| 2022 | — | −$0.45 | $0.00 | −$0.44 | — | $1.79 |
| 2023 | — | −$0.29 | $0.00 | −$0.32 | — | $1.21 |
| 2024 | — | −$0.47 | $0.00 | −$0.38 | — | $1.06 |
| 2025 | — | −$0.32 | $0.00 | −$0.31 | — | $1.43 |
Common questions about Trevi Therapeutics
How much does one share of Trevi Therapeutics earn?
Over the last 12 months, Trevi Therapeutics lost $0.34 for each share.
Does Trevi Therapeutics pay a dividend?
Trevi Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Trevi Therapeutics’s book value per share?
Trevi Therapeutics’s book value is $2.26 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Trevi Therapeutics have?
Each share of Trevi Therapeutics has $2.24 of cash and investments, as of June 30, 2026.
What is Trevi Therapeutics’s free cash flow per share?
−$0.36 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Trevi Therapeutics bought back shares?
Trevi Therapeutics’s share count rose about 30692% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.